174 related articles for article (PubMed ID: 25856425)
21. Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis.
Gaforio JJ; Serrano MJ; Sanchez-Rovira P; Sirvent A; Delgado-Rodriguez M; Campos M; de la Torre N; Algarra I; Dueñas R; Lozano A
Int J Cancer; 2003 Dec; 107(6):984-90. PubMed ID: 14601059
[TBL] [Abstract][Full Text] [Related]
22. Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients.
Tobin NP; Lindström LS; Carlson JW; Bjöhle J; Bergh J; Wennmalm K
Mol Oncol; 2014 May; 8(3):741-52. PubMed ID: 24630985
[TBL] [Abstract][Full Text] [Related]
23. Quantum dots-based tissue and in vivo imaging in breast cancer researches: current status and future perspectives.
Wang LW; Peng CW; Chen C; Li Y
Breast Cancer Res Treat; 2015 May; 151(1):7-17. PubMed ID: 25833213
[TBL] [Abstract][Full Text] [Related]
24. Quantitative tumor heterogeneity assessment on a nuclear population basis.
Wessel Lindberg AS; Conradsen K; Larsen R; Friis Lippert M; Røge R; Vyberg M
Cytometry A; 2017 Jun; 91(6):574-584. PubMed ID: 28141908
[TBL] [Abstract][Full Text] [Related]
25. Correlation of securin and Ki67 in invasive breast carcinoma.
Talaat IM; Hamoudi RA; Yakout NM; Oweiss NY; Omar AM
Histol Histopathol; 2019 Jun; 34(6):697-709. PubMed ID: 30506545
[TBL] [Abstract][Full Text] [Related]
26. Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study.
Klauschen F; Wienert S; Schmitt WD; Loibl S; Gerber B; Blohmer JU; Huober J; Rüdiger T; Erbstößer E; Mehta K; Lederer B; Dietel M; Denkert C; von Minckwitz G
Clin Cancer Res; 2015 Aug; 21(16):3651-7. PubMed ID: 25501130
[TBL] [Abstract][Full Text] [Related]
27. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
[TBL] [Abstract][Full Text] [Related]
28. Ki67 and proliferation in breast cancer.
Pathmanathan N; Balleine RL
J Clin Pathol; 2013 Jun; 66(6):512-6. PubMed ID: 23436927
[TBL] [Abstract][Full Text] [Related]
29. Relationship between the Ki67 index and its area based approximation in breast cancer.
Niazi MKK; Senaras C; Pennell M; Arole V; Tozbikian G; Gurcan MN
BMC Cancer; 2018 Sep; 18(1):867. PubMed ID: 30176814
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
31. MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups.
Aleskandarany MA; Rakha EA; Macmillan RD; Powe DG; Ellis IO; Green AR
Breast Cancer Res Treat; 2011 Jun; 127(3):591-9. PubMed ID: 20623333
[TBL] [Abstract][Full Text] [Related]
32. β-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases.
Bleckmann A; Conradi LC; Menck K; Schmick NA; Schubert A; Rietkötter E; Arackal J; Middel P; Schambony A; Liersch T; Homayounfar K; Beißbarth T; Klemm F; Binder C; Pukrop T
Clin Exp Metastasis; 2016 Apr; 33(4):309-23. PubMed ID: 26862065
[TBL] [Abstract][Full Text] [Related]
33. The potential utility of geminin as a predictive biomarker in breast cancer.
Sundara Rajan S; Hanby AM; Horgan K; Thygesen HH; Speirs V
Breast Cancer Res Treat; 2014 Jan; 143(1):91-8. PubMed ID: 24292956
[TBL] [Abstract][Full Text] [Related]
34. The alterations of cytokeratin and vimentin protein expressions in primary esophageal spindle cell carcinoma.
Li XM; Song X; Zhao XK; Hu SJ; Cheng R; Lv S; Du DF; Zhang XY; Lu JL; Ku JW; Zhang DY; Zhang Y; Fan ZM; Wang LD
BMC Cancer; 2018 Apr; 18(1):356. PubMed ID: 29609569
[TBL] [Abstract][Full Text] [Related]
35. Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma.
Laurinavicius A; Plancoulaine B; Rasmusson A; Besusparis J; Augulis R; Meskauskas R; Herlin P; Laurinaviciene A; Abdelhadi Muftah AA; Miligy I; Aleskandarany M; Rakha EA; Green AR; Ellis IO
Virchows Arch; 2016 Apr; 468(4):493-502. PubMed ID: 26818835
[TBL] [Abstract][Full Text] [Related]
36. Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility.
Hida AI; Bando K; Sugita A; Maeda T; Ueda N; Matsukage S; Nakanishi M; Kito K; Miyazaki T; Ohtsuki Y; Oshiro Y; Inoue H; Kawaguchi H; Yamashita N; Aogi K; Moriya T
J Clin Pathol; 2015 May; 68(5):356-61. PubMed ID: 25673730
[TBL] [Abstract][Full Text] [Related]
37. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays.
Knutsvik G; Stefansson IM; Aziz S; Arnes J; Eide J; Collett K; Akslen LA
PLoS One; 2014; 9(11):e112121. PubMed ID: 25375149
[TBL] [Abstract][Full Text] [Related]
39. Macroscopic optical physiological parameters correlate with microscopic proliferation and vessel area breast cancer signatures.
Chung SH; Feldman MD; Martinez D; Kim H; Putt ME; Busch DR; Tchou J; Czerniecki BJ; Schnall MD; Rosen MA; DeMichele A; Yodh AG; Choe R
Breast Cancer Res; 2015 May; 17():72. PubMed ID: 26013572
[TBL] [Abstract][Full Text] [Related]
40. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
